Published in Br J Cancer on April 24, 2007
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst (2009) 10.91
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68
-Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol (2015) 4.31
ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast Cancer Res (2010) 3.54
Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat (2013) 2.26
Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. Breast Cancer Res Treat (2011) 1.89
How reliable is Ki-67 immunohistochemistry in grade 2 breast carcinomas? A QA study of the Swiss Working Group of Breast- and Gynecopathologists. PLoS One (2012) 1.61
Absolute Benefit of Adjuvant Endocrine Therapies for Premenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: TEXT and SOFT Trials. J Clin Oncol (2016) 1.52
HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy. PLoS One (2015) 1.48
Reporting of prognostic studies of tumour markers: a review of published articles in relation to REMARK guidelines. Br J Cancer (2009) 1.46
Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer. BMC Clin Pathol (2011) 1.46
Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer. Br J Cancer (2012) 1.44
Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients. Breast Cancer Res (2008) 1.40
Absence of gamma-interferon-inducible lysosomal thiol reductase (GILT) is associated with poor disease-free survival in breast cancer patients. PLoS One (2014) 1.40
The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer. PLoS One (2015) 1.38
Risk estimation of distant metastasis in node-negative, estrogen receptor-positive breast cancer patients using an RT-PCR based prognostic expression signature. BMC Cancer (2008) 1.37
Ki-67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med (2010) 1.35
Biological Markers in DCIS and Risk of Breast Recurrence: A Systematic Review. J Cancer (2011) 1.32
Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study. Breast Cancer Res (2015) 1.29
Evaluation of microtubule-associated protein-Tau expression as a prognostic and predictive marker in the NSABP-B 28 randomized clinical trial. J Clin Oncol (2009) 1.25
Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012. Geburtshilfe Frauenheilkd (2013) 1.14
Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J (2008) 1.12
Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. Cancer Sci (2012) 1.05
KIAA0101 interacts with BRCA1 and regulates centrosome number. Mol Cancer Res (2011) 1.04
Protein expression profile and prevalence pattern of the molecular classes of breast cancer--a Saudi population based study. BMC Cancer (2010) 1.04
Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. Br J Cancer (2009) 1.04
RNA helicase DDX5 regulates microRNA expression and contributes to cytoskeletal reorganization in basal breast cancer cells. Mol Cell Proteomics (2011) 1.01
Prognostic value of Ki-67 in breast cancer patients with positive axillary lymph nodes: a retrospective cohort study. PLoS One (2014) 0.98
Long-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma. PLoS One (2013) 0.98
Cell proliferation, cell cycle abnormalities, and cancer outcome in patients with Barrett's esophagus: a long-term prospective study. Clin Cancer Res (2008) 0.98
Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer. J Cancer Res Clin Oncol (2008) 0.96
Large-scale RNA-Seq Transcriptome Analysis of 4043 Cancers and 548 Normal Tissue Controls across 12 TCGA Cancer Types. Sci Rep (2015) 0.95
Opposing effects of Runx2 and estradiol on breast cancer cell proliferation: in vitro identification of reciprocally regulated gene signature related to clinical letrozole responsiveness. Clin Cancer Res (2011) 0.95
Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer. Breast Cancer Res (2012) 0.95
Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer. Am J Pathol (2010) 0.94
The Interactions of Obesity, Inflammation and Insulin Resistance in Breast Cancer. Cancers (Basel) (2015) 0.93
Progesterone receptor status and Ki-67 index may predict early relapse in luminal B/HER2 negative breast cancer patients: a retrospective study. PLoS One (2014) 0.93
Nuclear location of tumor suppressor protein maspin inhibits proliferation of breast cancer cells without affecting proliferation of normal epithelial cells. BMC Cancer (2014) 0.92
Genetic polymorphisms of metastasis suppressor gene NME1 and breast cancer survival. Clin Cancer Res (2008) 0.92
An ICT infrastructure to integrate clinical and molecular data in oncology research. BMC Bioinformatics (2012) 0.92
Evaluation of Ki67 expression across distinct categories of breast cancer specimens: a population-based study of matched surgical specimens, core needle biopsies and tissue microarrays. PLoS One (2014) 0.92
MTBP is overexpressed in triple-negative breast cancer and contributes to its growth and survival. Mol Cancer Res (2014) 0.92
Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trial. Breast Cancer Res (2011) 0.91
LDL-cholesterol signaling induces breast cancer proliferation and invasion. Lipids Health Dis (2014) 0.91
Plasma level of LDL-cholesterol at diagnosis is a predictor factor of breast tumor progression. BMC Cancer (2014) 0.90
Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials (Review). Biomed Rep (2013) 0.90
Difference between Luminal A and Luminal B Subtypes According to Ki-67, Tumor Size, and Progesterone Receptor Negativity Providing Prognostic Information. Clin Med Insights Oncol (2014) 0.89
Prognostic significance of Ki-67 index value at the primary breast tumor in recurrent breast cancer. Mol Clin Oncol (2014) 0.89
The relationship between lymphovascular invasion and angiogenesis, hormone receptors, cell proliferation and survival in patients with primary operable invasive ductal breast cancer. BMC Clin Pathol (2013) 0.87
Intratumor cholesteryl ester accumulation is associated with human breast cancer proliferation and aggressive potential: a molecular and clinicopathological study. BMC Cancer (2015) 0.87
Genomic instability and proliferative activity as risk factors for distant metastases in breast cancer. Br J Cancer (2008) 0.87
A novel model for Ki67 assessment in breast cancer. Diagn Pathol (2014) 0.86
Recombinant lysyl oxidase propeptide protein inhibits growth and promotes apoptosis of pre-existing murine breast cancer xenografts. PLoS One (2012) 0.86
Ki-67 as a predictor of response to neoadjuvant chemotherapy in breast cancer patients. J Breast Cancer (2014) 0.85
Controlled breast cancer microarrays for the deconvolution of cellular multilayering and density effects upon drug responses. PLoS One (2012) 0.85
HSET overexpression fuels tumor progression via centrosome clustering-independent mechanisms in breast cancer patients. Oncotarget (2015) 0.85
Immunohistochemical expression of epithelial and stromal immunomodulatory signalling molecules is a prognostic indicator in breast cancer. BMC Res Notes (2012) 0.85
High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma: A Comprehensive Meta-Analysis with 13,053 Patients Involved. Medicine (Baltimore) (2016) 0.85
Up-regulation of kin17 is essential for proliferation of breast cancer. PLoS One (2011) 0.84
Biomarkers in triple negative breast cancer: A review. World J Clin Oncol (2015) 0.84
Integration of in vivo genotoxicity and short-term carcinogenicity assays using F344 gpt delta transgenic rats: in vivo mutagenicity of 2,4-diaminotoluene and 2,6-diaminotoluene structural isomers. Toxicol Sci (2009) 0.84
Histopathological subclassification of triple negative breast cancer using prognostic scoring system: five variables as candidates. Virchows Arch (2010) 0.84
An interobserver reproducibility analysis of Ki67 visual assessment in breast cancer. PLoS One (2015) 0.84
Proliferation marker securin identifies favourable outcome in invasive ductal breast cancer. Br J Cancer (2008) 0.84
Preoperative core needle biopsy is accurate in determining molecular subtypes in invasive breast cancer. BMC Cancer (2013) 0.83
Possible influence of mammographic density on local and locoregional recurrence of breast cancer. Breast Cancer Res (2013) 0.83
Respective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinoma. PLoS One (2012) 0.83
Evaluation of an Optimal Cut-Off Point for the Ki-67 Index as a Prognostic Factor in Primary Breast Cancer: A Retrospective Study. PLoS One (2015) 0.83
Clinicopathological and prognostic significance of high Ki-67 labeling index in hepatocellular carcinoma patients: a meta-analysis. Int J Clin Exp Med (2015) 0.82
Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up. Breast Cancer Res Treat (2016) 0.82
Clinical significance of miR-155 expression in breast cancer and effects of miR-155 ASO on cell viability and apoptosis. Oncol Rep (2012) 0.81
Molecular risk assessment of BIG 1-98 participants by expression profiling using RNA from archival tissue. BMC Cancer (2010) 0.81
Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma. Br J Cancer (2015) 0.81
The prognostic role of Ki-67/MIB-1 in cervical cancer: a systematic review with meta-analysis. Med Sci Monit (2015) 0.81
[Determination of proliferation in breast cancer by immunohistochemical detection of Ki-67]. Pathologe (2014) 0.81
MicroRNA-130b targets PTEN to mediate drug resistance and proliferation of breast cancer cells via the PI3K/Akt signaling pathway. Sci Rep (2017) 0.80
14-3-3ζ orchestrates mammary tumor onset and progression via miR-221-mediated cell proliferation. Cancer Res (2013) 0.80
Joint detection of multiple immunohistochemical indices and clinical significance in breast cancer. Mol Clin Oncol (2013) 0.80
Equol inhibits proliferation of human gastric carcinoma cells via modulating Akt pathway. World J Gastroenterol (2015) 0.80
Molecular classification of breast cancer. Virchows Arch (2014) 0.80
HER2/HER3 heterodimers and p21 expression are capable of predicting adjuvant trastuzumab response in HER2+ breast cancer. Breast Cancer Res Treat (2014) 0.79
HER-2 positive breast cancer is associated with an increased risk of positive cavity margins after initial lumpectomy. World J Surg Oncol (2014) 0.79
Cell Proliferation (KI-67) Expression Is Associated with Poorer Prognosis in Nigerian Compared to British Breast Cancer Women. ISRN Oncol (2013) 0.78
Factors that predict early treatment failure for patients with locally advanced (T4) breast cancer. Br J Cancer (2008) 0.78
[Assessment of proliferation: core biopsy or resection specimen? Discrepancies in breast cancer with low and high proliferation]. Pathologe (2012) 0.78
Prognostic impact of discrepant Ki67 and mitotic index on hormone receptor-positive, HER2-negative breast carcinoma. Br J Cancer (2015) 0.78
Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin. Sci Rep (2016) 0.78
Multivariate meta-analysis of prognostic factor studies with multiple cut-points and/or methods of measurement. Stat Med (2015) 0.78
Expression and prognostic value of the Ki-67 in Wilms' tumor: experience with 48 cases. Pediatr Surg Int (2010) 0.78
Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy. Int J Clin Exp Pathol (2014) 0.78
Clinical Significance of Microcalcifications Detection in Invasive Breast Carcinoma. Yonago Acta Med (2015) 0.77
The Expression of Carbonic Anhydrase (CA) IX/XII and Lymph Node Metastasis in Early Breast Cancer. Cancer Res Treat (2015) 0.77
Survivin, Ki-67 and tumor grade as predictors of response to docetaxel-based neoadjuvant chemotherapy in locally advanced breast cancer. Mol Clin Oncol (2013) 0.77
Phytohemagglutinin-induced mitotic index in blood lymphocytes: a potential biomarker for breast cancer risk. Breast Cancer (Auckl) (2010) 0.77
USP14 is a predictor of recurrence in endometrial cancer and a molecular target for endometrial cancer treatment. Oncotarget (2016) 0.77
Digital imaging in the immunohistochemical evaluation of the proliferation markers Ki67, MCM2 and Geminin, in early breast cancer, and their putative prognostic value. BMC Cancer (2015) 0.77
Prognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups. Breast Cancer Res (2016) 0.77
The combination of Ki67, histological grade and estrogen receptor status identifies a low-risk group among 1,854 chemo-naïve women with N0/N1 primary breast cancer. Springerplus (2013) 0.77
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet (2005) 42.90
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med (2004) 41.02
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med (1998) 19.07
Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis (1985) 19.03
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol (2006) 16.25
Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A (1999) 14.16
An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci U S A (2005) 13.54
Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer (1983) 11.19
Language bias in randomised controlled trials published in English and German. Lancet (1997) 7.29
Reporting recommendations for tumor marker prognostic studies. J Clin Oncol (2005) 6.31
Meta-analysis of the literature or of individual patient data: is there a difference? Lancet (1993) 6.16
Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol (1992) 6.13
Invited commentary: a critical look at some popular meta-analytic methods. Am J Epidemiol (1994) 6.01
Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer. J Clin Invest (2005) 5.90
National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst (2001) 5.09
Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol (2006) 4.84
Proliferation marker Ki-67 in early breast cancer. J Clin Oncol (2005) 4.74
Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol (2003) 3.90
Common markers of proliferation. Nat Rev Cancer (2006) 3.85
Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer (2003) 3.47
Selecting the language of the publications included in a meta-analysis: is there a Tower of Babel bias? J Clin Epidemiol (1995) 3.38
Angiogenesis as a prognostic marker in breast carcinoma with conventional adjuvant chemotherapy: a multiparametric and immunohistochemical analysis. J Pathol (1998) 2.40
Macrophage infiltration and its prognostic implications in breast cancer: the relationship with VEGF expression and microvessel density. Oncol Rep (2005) 2.31
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol (2005) 2.07
Ki67 immunostaining in primary breast cancer: pathological and clinical associations. Br J Cancer (1989) 1.97
Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors--a surrogate marker? Cancer (2003) 1.88
Prognostic and predictive effects of immunohistochemical factors in high-risk primary breast cancer patients. Clin Cancer Res (2006) 1.75
Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences. Eur J Cancer (1993) 1.66
Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis: associations with other prognostic factors and survival. Br J Cancer (1995) 1.60
Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. Cancer (1991) 1.57
Proliferation markers in breast carcinoma. Mitotic figure count, S-phase fraction, proliferating cell nuclear antigen, Ki-67 and MIB-1. Am J Clin Pathol (1995) 1.50
Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer (1991) 1.48
Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer (2002) 1.43
The utility of mitotic index, oestrogen receptor and Ki-67 measurements in the creation of novel prognostic indices for node-negative breast cancer. Eur J Surg Oncol (1999) 1.40
Prognostic and predictive factors revisited. Breast (2005) 1.39
Correlation between MIB-1 and other proliferation markers: clinical implications of the MIB-1 cutoff value. Cancer (2002) 1.39
Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res (2001) 1.37
Meta-analyses based on abstracted data: a step in the right direction, but only a first step. J Clin Oncol (2004) 1.30
Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma. Cancer (2004) 1.30
Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer (1993) 1.28
The prognostic value of proliferation indices: a study with in vivo bromodeoxyuridine and Ki-67. Breast Cancer Res Treat (2000) 1.27
Prognostic significance of tumor cell proliferation rate as determined by the MIB-1 antibody in breast carcinoma: its relationship with vimentin and p53 protein. Clin Cancer Res (1996) 1.27
Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res (1996) 1.26
Minichromosome maintenance protein 2 is a strong independent prognostic marker in breast cancer. J Clin Oncol (2003) 1.24
Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol (1999) 1.24
MIB-1 labelling index is an independent prognostic marker in primary breast cancer. Br J Cancer (1998) 1.21
Hypoxia inducible factor-1alpha is a prognostic marker in premenopausal patients with intermediate to highly differentiated breast cancer but not a predictive marker for tamoxifen response. Int J Cancer (2006) 1.20
Ki-67, p53, Er-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol (1997) 1.17
The prognostic value of oncogenic antigen 519 (OA-519) expression and proliferative activity detected by antibody MIB-1 in node-negative breast cancer. J Pathol (1995) 1.16
Ki-67 immunostaining in 322 primary breast cancers: associations with clinical and pathological variables and prognosis. Int J Cancer (1997) 1.12
Lack of prognostic significance of the monoclonal antibody Ki-S1, a novel marker of proliferative activity, in node-negative breast carcinoma. Breast Cancer Res Treat (1996) 1.12
p21WAF1 expression in invasive breast cancer and its association with p53, AP-2, cell proliferation, and prognosis. J Clin Pathol (2003) 1.09
From science to practice. Meta-analyses using individual patient data are needed. JAMA (1995) 1.09
Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival. Clin Cancer Res (2004) 1.09
Ki67 immunoreactivity in breast carcinoma: relationships to prognostic variables and short term survival. Eur J Surg Oncol (1992) 1.09
The important prognostic value of Ki-67 expression as determined by image analysis in breast cancer. J Cancer Res Clin Oncol (1996) 1.08
The prognostic value of p53 and c-erbB-2 expression, proliferative activity and angiogenesis in node-negative breast carcinoma. Tumori (2005) 1.02
Usefulness of immunohistochemical staining for p53 in the prognosis of breast carcinomas: correlations with established prognosis parameters and with the proliferation marker, MIB-1. Gynecol Oncol (1995) 1.02
Association between histology grade, expression of HsMCM2, and cyclin A in human invasive breast carcinomas. J Clin Pathol (2003) 1.01
MIB-1 proliferative activity in invasive breast cancer measured by image analysis. J Clin Pathol (1996) 0.99
Standards for reporting prognostic tumor marker studies. J Clin Oncol (2005) 0.98
Immunohistochemical evaluation of growth fractions in human breast cancers using monoclonal antibody Ki-67. Breast Cancer Res Treat (1991) 0.98
Risk-group discrimination in node-negative breast cancer using invasion and proliferation markers: 6-year median follow-up. Br J Cancer (1999) 0.98
Growth fractions (Ki-67) in primary breast cancers, with particular reference to node-negative tumors. Cancer Detect Prev (1995) 0.97
Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat (1996) 0.97
Prognostic comparative study of S-phase fraction and Ki-67 index in breast carcinoma. J Clin Pathol (2001) 0.97
Analysis of correlation between mitotic index, MIB1 score and S-phase fraction as proliferation markers in invasive breast carcinoma. Methodological aspects and prognostic value in a series of 257 cases. Anticancer Res (2004) 0.96
AgNORs in breast tumours. Micron (2000) 0.96
Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases. Breast Cancer Res Treat (1999) 0.96
Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res Treat (1996) 0.95
Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int J Cancer (1996) 0.94
Low levels of cell cycle inhibitor p27kip1 combined with high levels of Ki-67 predict shortened disease-free survival in T1 and T2 invasive breast carcinomas. Int J Oncol (2001) 0.93
Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer. Br J Cancer (1992) 0.92
Flow cytometry and quantitative immunohistochemical study of cell cycle regulation proteins in invasive breast carcinoma: prognostic significance. Cancer (2003) 0.91
Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis. Breast Cancer Res Treat (1994) 0.91
Role of P53 and BCL-2 in high-risk breast cancer patients treated with adjuvant anthracycline-based chemotherapy. J Cancer Res Clin Oncol (2000) 0.91
Bcl-2 immunostaining: a way to finding unresponsive postmenopausal N+ breast cancer patients. Anticancer Res (2000) 0.88
Prognostic value of Bcl-2 in invasive breast cancer receiving chemotherapy and endocrine therapy. Oncol Rep (2002) 0.87
Immunologic proliferation marker Ki-S2 as prognostic indicator for lymph node-negative breast cancer. J Natl Cancer Inst (1999) 0.87
Comparative prognostic value of Ki-67 and MIB-1 proliferation indices in breast cancer. Anticancer Res (1996) 0.86
Prognostic value of different factors in breast carcinoma. Tumori (2004) 0.86
Vimentin expression does not assist in predicting survival in ductal carcinoma of the breast. Pathology (2002) 0.85
Prognostic value of vascular density and cell proliferation in breast cancer patients. Pathol Res Pract (1999) 0.84
ESMO Minimum Clinical Recommendations for diagnosis, adjuvant treatment and follow-up of primary breast cancer. Ann Oncol (2005) 0.83
Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer. Breast Cancer Res Treat (2002) 0.83
A multiparametric study on the prognostic value of epidermal growth factor receptor in operable breast carcinoma. Breast Cancer Res Treat (1994) 0.82
Prognostic relevance of immunohistology, tumor size and vascular space involvement in axillary node negative breast cancer. Arch Gynecol Obstet (1998) 0.81
[The specificity of expression of molecular biological markers in tumors of the mammary gland]. Vestn Ross Akad Med Nauk (2004) 0.80
[In situ determination of the Ki-67 growth fraction (Ki-67 GF) in human tumors (studies in breast cancer)]. Acta Histochem Suppl (1990) 0.80
LEA.135 expression: its comparison with other prognostic biomarkers for patients with primary breast carcinoma. Anticancer Res (2000) 0.79
p53 expression is of independent predictive value in lymph node-negative breast carcinoma. Eur J Cancer (1997) 0.79
[Predictive variables of lymphatic metastasis in breast carcinoma with a diameter below 2 cm]. Suppl Tumori (2006) 0.78
[Correlation of size of the primary tumor and axillary node status with the p53 tumor suppressor gene in carcinoma of the breast]. Vojnosanit Pregl (2002) 0.78
The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol (2000) 3.69
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2005) 3.40
Psychosocial correlates of oestrogen and progesterone receptors in breast cancer. Lancet (1990) 3.14
Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J (2001) 3.04
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol (2002) 3.03
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2011) 2.80
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol (2013) 2.66
Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol (2000) 2.41
A comparative study of survival models for breast cancer prognostication based on microarray data: does a single gene beat them all? Bioinformatics (2008) 2.34
Maintenance chemotherapy for small cell lung cancer: a critical review of the literature. Lung Cancer (1998) 2.27
Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol (2005) 2.07
Association between antifungal prophylaxis and rate of documented bacteremia in febrile neutropenic cancer patients. Clin Infect Dis (2001) 2.03
Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis. Ann Oncol (2006) 1.92
Survival improvement in resectable non-small cell lung cancer with (neo)adjuvant chemotherapy: results of a meta-analysis of the literature. Lung Cancer (2005) 1.92
Ki-67 expression and patients survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer (2004) 1.79
Outcome after stereotactic thalamotomy for parkinsonian, essential, and other types of tremor. Neurosurgery (1995) 1.72
Long-term toxic effects of adjuvant chemotherapy in breast cancer. Ann Oncol (2011) 1.71
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann Oncol (2012) 1.69
Scoring systems in cancer patients admitted for an acute complication in a medical intensive care unit. Crit Care Med (2000) 1.69
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol (2008) 1.66
Hemifacial spasm and arterial hypertension. Mov Disord (1999) 1.63
The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J (2002) 1.57
Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents (2007) 1.57
Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: distinct, overlapping or same populations. Oncogene (2011) 1.56
Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2003) 1.54
The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer (2002) 1.52
CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients. Br J Cancer (2004) 1.52
Prophylactic cranial irradiation in small cell lung cancer: a systematic review of the literature with meta-analysis. BMC Cancer (2001) 1.44
Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation. Breast (2004) 1.42
Role of granulocyte and granulocyte-macrophage colony-stimulating factors in the treatment of small-cell lung cancer: a systematic review of the literature with methodological assessment and meta-analysis. Lung Cancer (2002) 1.40
[EGF-R expression correlation between biopsy and surgical specimens of lung carcinoma]. Rev Mal Respir (2003) 1.39
Gene array of VHL mutation and hypoxia shows novel hypoxia-induced genes and that cyclin D1 is a VHL target gene. Br J Cancer (2004) 1.39
Anti-basal ganglia antibodies in acute and persistent Sydenham's chorea. Neurology (2002) 1.38
Understanding the biology of triple-negative breast cancer. Ann Oncol (2012) 1.31
Piperacillin-tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulocytopenic patients with cancer. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Antimicrob Agents Chemother (1995) 1.31
A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis. Lung Cancer (2000) 1.27
A prospective study on hyponatraemia in medical cancer patients: epidemiology, aetiology and differential diagnosis. Support Care Cancer (2000) 1.26
Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol (2001) 1.26
Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries. Ann Oncol (2011) 1.24
High concordance of protein (by IHC), gene (by FISH; HER2 only), and microarray readout (by TargetPrint) of ER, PgR, and HER2: results from the EORTC 10041/BIG 03-04 MINDACT trial. Ann Oncol (2014) 1.24
Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival. Ann Oncol (2008) 1.23
EGFR, pMAPK, pAkt and PTEN status by immunohistochemistry: correlation with clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Ann Oncol (2009) 1.23
Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann Oncol (2001) 1.23
Reliability of the tissue microarray based FISH for evaluation of the HER-2 oncogene in breast carcinoma. J Clin Pathol (2002) 1.22
Understanding the molecular basis of histologic grade. Pathobiology (2008) 1.20
BRCA in breast cancer: ESMO Clinical Practice Guidelines. Ann Oncol (2011) 1.20
Serial FDG-PET/CT for early outcome prediction in patients with metastatic colorectal cancer undergoing chemotherapy. Ann Oncol (2011) 1.19
The effects of a 24-h psychological training program on attitudes, communication skills and occupational stress in oncology: a randomised study. Eur J Cancer (1993) 1.18
The predictive value of HER2 in breast cancer. Oncology (2001) 1.15
Sensitivity of HER-2/neu antibodies in archival tissue samples of invasive breast carcinomas. Correlation with oncogene amplification in 160 cases. Am J Clin Pathol (2000) 1.15
The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature. Br J Cancer (2003) 1.14
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer (2002) 1.13
HER-2/neu as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Breast Cancer Res Treat (2004) 1.12
Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study. Bone Marrow Transplant (2010) 1.11
Absence of Epstein-Barr virus in medullary carcinoma of the breast as demonstrated by immunophenotyping, in situ hybridization and polymerase chain reaction. Am J Clin Pathol (1995) 1.09
A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies. Ann Oncol (2009) 1.08
Response to chemotherapy, quality of life benefits and survival in advanced non-small cell lung cancer: review of literature results. Lung Cancer (2001) 1.08
Tumor-infiltrating dendritic cells in adenocarcinomas of the breast: a study of 143 neoplasms with a correlation to usual prognostic factors and to clinical outcome. Int J Cancer (1999) 1.08
Screening for psychiatric disorders in a lymphoma out-patient population. Eur J Cancer (1992) 1.08
HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol (2001) 1.07
Poststreptococcal acute disseminated encephalomyelitis with basal ganglia involvement and auto-reactive antibasal ganglia antibodies. Ann Neurol (2001) 1.06
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial. Ann Oncol (2007) 1.06
Relationship between cotinine levels, household and personal smoking habit and season in 9-14 year old children. Eur Respir J (1994) 1.06
Evidence-based guidelines for interpreting change scores for the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Eur J Cancer (2012) 1.06
The landscape of medical oncology in Europe by 2020. Ann Oncol (2014) 1.05
[VEGF and survival of patients with lung cancer: a systematic literature review and meta-analysis]. Rev Mal Respir (2002) 1.05
Oral contraceptive induced chorea: another condition associated with anti-basal ganglia antibodies. J Neurol Neurosurg Psychiatry (2004) 1.05
Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Int J Oncol (2004) 1.04
Interleukins-6 and -11 expression in primary breast cancer and subsequent development of bone metastases. Cancer Lett (2001) 1.03
Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase I/II dose-escalation study. Br J Cancer (2008) 1.02
Advanced epithelial ovarian cancer: 1998 consensus statements. Ann Oncol (1999) 1.02
Novel therapeutic strategies targeting the epidermal growth factor receptor (EGFR) family and its downstream effectors in breast cancer. Ann Oncol (2003) 1.01